Google
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™
Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today that it will provide financial assistance to help eligible patients afford their monthly co-payment for Endari™ (L-glutamine oral powder)1. The program is limited to financially eligible patients covered by commercial insurance.
A significant number of individuals with sickle cell disease are covered by commercial insurance. In some cases, patients may have difficulty affording the monthly co-payment amount.
Mark Diamond, Emmaus’ Vice President of Commercialization, commented: “We are committed to removing barriers between patients and Endari – giving a greater number of patients access to our effective treatment for sickle cell disease.”
+myBinderRelated Content
-
GBT launches ACCEL grants program to improve access to care for people with Sickle cell diseaseGlobal Blood Therapeutics, Inc. (GBT) to...
-
The Sickle Cell Association of KentuckianaThe Sickle Cell Association of Kentuckia...
-
Sickle Cell Disease Coalition (SCDC)https://www.youtube.com/watch?v=oQP-Uq0B...
-
New York State Sickle Cell Advocacy Network (NYSSCAN)New York State Sickle Cell Advocacy Netw...
-
2019-2021 ASH Clinical Practice Guidelines on Sickle Cell Disease: What You Should KnowThe American Society of Hematology (ASH)...
-
Hertz NazaireHertz Nazaire Hertz was born in Port-Au-...
-
Etta PeteEtta Pete is Executive Director at South...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.